Tag
A novel conversation aid was developed and refined iteratively with patients and physicians to support shared decision-making for low carbon footprint inhaler prescribing in asthma and COPD, balancing environmental impact with safety and pa
This article reviews mepolizumab efficacy in COPD patients with variable blood eosinophil counts, showing benefits even with intermittent eosinophilia, expanding treatable phenotypes beyond persistent elevation.
CT-derived pulmonary vascular metrics, especially the small-artery to total arterial volume ratio, identify severe pulmonary hypertension in chronic lung disease, with distinct vascular remodeling patterns in COPD and fibrosing ILD.
A large pooled US cohort study found that COPD substantially reduces life expectancy, even among never-smokers, with years of life lost increasing progressively from GOLD stage 1 through stage 4.
Portable HEPA air cleaners plus motivational interviewing improved symptoms and quality of life in smokers with COPD by reducing indoor particulate matter, though lung function and exacerbations did not significantly change.
COPD exacerbations significantly increase cardiovascular risk for months. This article examines the link between COPD and heart disease, emphasizing proactive screening during flare-ups and evidence-based prevention strategies to improve su
Community-based COPD patients with mild or single moderate exacerbations show higher future exacerbation risks and lung structural abnormalities, despite stable lung function decline rates.
A large observational study finds that once-daily umeclidinium-vilanterol dry powder inhaler significantly reduces COPD exacerbation risk compared to glycopyrrolate-formoterol and tiotropium-olodaterol, while maintaining similar safety prof
A new clinical prediction model identifies prior recurrent falls, multimorbidity, and impaired dual-task mobility as key predictors of future falls in patients with COPD, offering a new tool for targeted geriatric intervention in respirator
Recent evidence reveals that COPD in adults under 50 is more prevalent than previously thought, significantly increasing the risk of premature death and heart failure. Furthermore, impaired lung function trajectories starting in childhood p
A randomized trial demonstrates that a smartphone app-based pulmonary rehabilitation program significantly improves quality of life and physical activity in patients with chronic respiratory diseases, offering a scalable alternative to trad
A 12-week randomized controlled trial reveals that smartphone-based pulmonary rehabilitation significantly improves quality of life and physical activity in patients with chronic respiratory diseases, offering a scalable and feasible altern
A randomized trial shows that a six-month personalised community-based physical activity programme sustains physical activity improvements and functional performance post-pulmonary rehabilitation in COPD patients, though other health benefi
This pilot randomized trial investigates the safety, feasibility, and efficacy of high intensity interval training modalities compared to constant-load endurance training in COPD patients with chronic respiratory failure, revealing promisin
Cytisinicline significantly improves smoking cessation rates and is well tolerated in smokers with self-reported COPD, supporting its use as an effective treatment option for this high-risk population.
Mepolizumab significantly reduces moderate to severe COPD exacerbations in patients with elevated eosinophils on triple inhaled therapy, marking a promising advance for eosinophilic COPD management.
The PROSA 2 trial demonstrates that high-flow nasal oxygen significantly reduces hypoxaemia time and events compared to conventional low-flow oxygen in COPD patients undergoing bronchoscopy, improving procedural safety without compromising
This study elucidates that airway eosinophilia in COPD is linked to enhanced type 2 inflammation in airway epithelium and predicts responsiveness to inhaled corticosteroids, revealing a distinct COPD endotype with potential for precision th
A randomized crossover trial reveals low-dose morphine in COPD does not improve sleep efficiency or breathlessness but may cause nocturnal hypoventilation, raising safety concerns despite unchanged next-day alertness.
Add-on dupilumab significantly improves health-related quality of life and respiratory symptoms in COPD patients with type 2 inflammation, according to pooled results from the BOREAS and NOTUS phase 3 trials.
